Predictive and modifying factors of bone mineral density decline in patients with COPD

Respir Med. 2019 Mar:148:13-23. doi: 10.1016/j.rmed.2019.01.005. Epub 2019 Jan 17.

Abstract

Rationale: Various determinants of osteoporosis have been previously identified. However, only a few longitudinal studies have examined related factors. We aimed to investigate factors predicting and modifying rapid decline of bone mineral density in patients with chronic obstructive pulmonary disease.

Methods: We analyzed patients with chronic obstructive pulmonary disease whose bone mineral density were measured at least three times over three years (n = 111). We divided annual per cent changes of bone mineral density in different body parts into tertiles. Rapid decliners (n = 33) were defined as those with the largest decline in at least two parts; all other participants were defined as non-rapid decliners (n = 78).

Results: At enrollment, bone mineral density did not differ between the two groups. However, rapid decliners had a significantly greater rate of new vertebral fractures over 3 years compared with non-rapid decliners. On multivariate logistic regression analysis, age, moderate to severe emphysema, no daily exercise habits, and anemia increased the likelihood of rapid decliners. Furthermore, patients who newly started and continued bisphosphonate exhibited higher annual per cent changes of bone mineral density than did those without bisphosphonate use.

Conclusions: A rapid decline in bone mineral density correlates to a higher likelihood of vertebral fracture. We clarified the predictors of bone mineral density decline and demonstrated that bisphosphonate use might modify bone mineral density in patients with chronic obstructive pulmonary disease.

Keywords: Bisphosphonate; COPD; Comorbidity; Osteoporosis; Vertebral fracture.

Publication types

  • Comparative Study
  • Observational Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bone Density / drug effects*
  • Bone Density / physiology
  • Bone Density Conservation Agents / administration & dosage
  • Bone Density Conservation Agents / adverse effects
  • Bone Density Conservation Agents / therapeutic use
  • Comorbidity
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Osteoporosis / diagnostic imaging*
  • Osteoporosis / drug therapy
  • Osteoporosis / etiology
  • Predictive Value of Tests
  • Prevalence
  • Prospective Studies
  • Pulmonary Disease, Chronic Obstructive / complications*
  • Pulmonary Disease, Chronic Obstructive / epidemiology
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Pulmonary Emphysema / diagnostic imaging*
  • Pulmonary Emphysema / epidemiology
  • Risedronic Acid / administration & dosage
  • Risedronic Acid / adverse effects
  • Risedronic Acid / therapeutic use
  • Spinal Fractures / diagnostic imaging*
  • Spinal Fractures / epidemiology

Substances

  • Bone Density Conservation Agents
  • Risedronic Acid